肉瘤患者的二次血液性恶性瘤:单中心回顾性研究
Yoon Jung Jang1, Hong Kyu Jeong1,2, Chang-Bae Kong3
1Department of Hematology and Oncology, Korea Cancer Center Hospital, Korea Institute of Radiological and Medical Sciences, Seoul 01812, Republic of Korea.
Oncology letters
|April 4, 2024
概括
其次性血液性恶性瘤 (SHMs) 发生在0.6%的肉瘤患者中. 这些SHM显著恶化患者的预后,特别是如果不治疗,突出需要警监测.
科学领域:
- 在瘤学瘤学.
- 血液学 血液学 血液学
背景情况:
- 肉瘤患者在治疗后面临发展二次血液性恶性瘤 (SHM) 的风险.
- 了解瘤中SHM的发生率,特征和结果对于患者管理至关重要.
研究的目的:
- 调查治疗肉瘤的患者中SHM的临床特征和预后.
- 为了确定瘤诊断和治疗后的SHM的发病率和常见类型.
主要方法:
- 追溯性研究分析了被诊断为SHMs的肉瘤患者的医疗记录.
- 数据收集的重点是患者人口统计学,肉瘤类型,SHM发病率,潜伏期,治疗和生存结果.
主要成果:
- 在2,953名肉瘤患者中,有18名 (0.6%) 患有SHMs.
- 急性骨髓性白血病和骨髓质疏松综合征是最常见的SHMs.
- SHM的存在与预后较差有关,特别是如果没有特定的SHM治疗.
结论:
- 肉瘤患者中SHM的发生率很低,但具有显著的负面预后影响.
- 及时诊断和治疗SHMs对于改善肉瘤幸存者的生存率至关重要.
- 对瘤患者的SHM风险因素和预防策略的进一步研究是有必要的.
相关概念视频
Hematopoiesis
5.3K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
5.3K
Bone Marrow Sampling and Transplants
328
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
328
Regulation of Hematopoietic Stem Cells
3.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.2K


